DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Patent 7,988,001 protects COMBIVENT RESPIMAT, STIOLTO RESPIMAT, STRIVERDI RESPIMAT, and SPIRIVA RESPIMAT, and is included in four NDAs.
Protection for SPIRIVA RESPIMAT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-seven patent family members in thirty-six countries.
Summary for Patent: 7,988,001
|Title:||Container provided with a pressure equalization opening|
|Abstract:||A process for producing a container comprising an outer container, an inner bag disposed therein and a pressure equalisation opening disposed in the outer container, and a container produced according to this process, is described, wherein a pre-moulding, comprising two coaxial tubes, is first produced by co-extrusion with the help of a blow mould and with an outwardly-projecting base seam being formed. The process forms a pressure equalisation opening in the outer container without endangering the integrity of the container, wherein a lower wastage rate and higher productivity are achieved. To do this, the base seam is partially cut off and a force which acts in the direction of the seam is introduced into the pre-moulding, which has a temperature of 40 degrees C. to 70 degrees C., which force breaks open and plastically deforms the base seam so that a pressure equalisation opening is formed in the base area.|
|Inventor(s):||Kuehn; Torsten (Ingelheim, DE), Metzger; Burkhard Peter (Ingelheim, DE)|
|Assignee:||Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, DE)|
Patent Claim Types:|
see list of patent claims
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Patented / Exclusive Use||Submissiondate|
|Boehringer Ingelheim||COMBIVENT RESPIMAT||albuterol sulfate; ipratropium bromide||SPRAY, METERED;INHALATION||021747-001||Oct 7, 2011||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|Boehringer Ingelheim||STIOLTO RESPIMAT||olodaterol hydrochloride; tiotropium bromide||SPRAY, METERED;INHALATION||206756-001||May 21, 2015||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|Boehringer Ingelheim||STRIVERDI RESPIMAT||olodaterol hydrochloride||SPRAY, METERED;INHALATION||203108-001||Jul 31, 2014||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Patented / Exclusive Use||>Submissiondate|
Foreign Priority and PCT Information for Patent: 7,988,001
|Country||Patent Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|>Country||>Patent Number||>Estimated Expiration||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration|